Equities analysts expect that HealthEquity, Inc. (NASDAQ:HQY) will post sales of $55.50 million for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for HealthEquity’s earnings. The lowest sales estimate is $54.79 million and the highest is $56.20 million. HealthEquity reported sales of $43.36 million in the same quarter last year, which indicates a positive year-over-year growth rate of 28%. The business is scheduled to issue its next earnings results on Tuesday, December 5th.

According to Zacks, analysts expect that HealthEquity will report full year sales of $55.50 million for the current financial year, with estimates ranging from $224.18 million to $227.95 million. For the next financial year, analysts anticipate that the business will post sales of $276.51 million per share, with estimates ranging from $267.39 million to $282.98 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover HealthEquity.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.13. HealthEquity had a return on equity of 13.93% and a net margin of 20.27%. The firm had revenue of $56.90 million during the quarter, compared to the consensus estimate of $55.66 million. During the same quarter in the prior year, the company earned $0.16 EPS. The firm’s revenue for the quarter was up 28.7% compared to the same quarter last year.

A number of brokerages have weighed in on HQY. BidaskClub raised HealthEquity from a “strong sell” rating to a “sell” rating in a research report on Friday. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $61.00 price target (up previously from $57.00) on shares of HealthEquity in a research report on Monday, June 12th. Cantor Fitzgerald boosted their price target on HealthEquity from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 7th. Zacks Investment Research raised HealthEquity from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Wednesday, July 12th. Finally, Chardan Capital boosted their price target on HealthEquity from $53.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, June 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $56.50.

In related news, major shareholder Berkley Capital, Llc sold 4,002 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $51.99, for a total value of $208,063.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stephen Neeleman sold 8,500 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $50.83, for a total value of $432,055.00. Following the completion of the sale, the insider now owns 1,000 shares of the company’s stock, valued at $50,830. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,976,064 shares of company stock valued at $100,665,521. Corporate insiders own 29.00% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of HealthEquity by 6.2% in the first quarter. Vanguard Group Inc. now owns 4,115,237 shares of the company’s stock valued at $174,691,000 after buying an additional 240,136 shares during the period. Paloma Partners Management Co bought a new stake in shares of HealthEquity in the first quarter valued at approximately $503,000. First Trust Advisors LP boosted its stake in shares of HealthEquity by 17.0% in the second quarter. First Trust Advisors LP now owns 94,283 shares of the company’s stock valued at $4,698,000 after buying an additional 13,676 shares during the period. Royce & Associates LP boosted its stake in shares of HealthEquity by 18.0% in the second quarter. Royce & Associates LP now owns 139,200 shares of the company’s stock valued at $6,936,000 after buying an additional 21,200 shares during the period. Finally, Turner Investments LLC bought a new stake in shares of HealthEquity in the second quarter valued at approximately $374,000. Institutional investors and hedge funds own 91.86% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/15/55-50-million-in-sales-expected-for-healthequity-inc-hqy-this-quarter.html.

Shares of HealthEquity (HQY) opened at 45.81 on Friday. The company has a market cap of $2.75 billion, a P/E ratio of 86.11 and a beta of 1.75. The company’s 50-day moving average price is $44.70 and its 200 day moving average price is $45.92. HealthEquity has a 52 week low of $30.34 and a 52 week high of $54.95.

About HealthEquity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Get a free copy of the Zacks research report on HealthEquity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.